Profiles
Professor Matthew Cramp
Chair in Hepatology
Biomedical Research - Institute of Translational & Stratified Medicine (Faculty of Medicine and Dentistry)
Key publications are highlighted
Journals
Articles
2018
'Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK'
LANCET
392,
(10162)
2398-2412
, DOI
2018
'Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom'
Aliment Pharmacol Ther
48,
(9)
951-960
, DOI
2018
'Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score'
The Lancet Gastroenterology & Hepatology
, DOI
2018
'Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial'
Hepatology
67,
(6)
2113-2126
, DOI
2018
'Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK'
The Lancet
391,
(10125)
1097-1107
, DOI
2017
'Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood'
Journal of Viral Hepatitis
25,
(3)
245-253
, DOI
2017
'Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection'
Scientific Reports
7,
, DOI
PEARL
2017
'Lipid interactions influence hepatitis C virus susceptibility and resistance to infection'
Clinical Liver Disease
10,
(1)
17-20
, DOI
PEARL
2017
'Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users'
Journal of Viral Hepatitis
, DOI
PEARL
2017
'Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study'
The Lancet Gastroenterology & Hepatology
2,
(5)
325-336
, DOI
2017
'New metrics for the Lancet Standing Commission on Liver Disease in the UK'
The Lancet
389,
(10083)
2053-2080
, DOI
2017
'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study'
The Lancet Gastroenterology & Hepatology
2,
(3)
161-176
, DOI
2017
'Infection does not increase long-term mortality in patients with acute severe alcoholic hepatitis treated with corticosteroids'
World Journal of Gastroenterology
23,
(11)
2052-2052
, DOI
PEARL
2017
'Hepatorenal syndrome: Update on diagnosis and therapy'
World Journal of Hepatology
9,
(6)
293-293
, DOI
PEARL
2016
'Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy'
Journal of Clinical and Experimental Hepatology
6,
(3)
186-194
, DOI
2016
'Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection'
Journal of Viral Hepatitis
23,
(11)
873-880
, DOI
PEARL
2015
'Diagnosis and management of hepatitis C'
British Journal of Hospital Medicine
76,
(11)
625-630
, DOI
2015
'Implementation of the Lancet Standing Commission on Liver Disease in the UK'
The Lancet
386,
(10008)
2098-2111
, DOI
2015
'The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis'
Hepatology
63,
(3)
930-950
, DOI
2015
'International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways'
Nature Communications
6,
(1)
, DOI
PEARL
2015
'Haplotype analysis finds linkage disequilibrium in the IL-12 gene in patients with HCV'
J Med Virol
87,
(7)
1207-1217
, DOI
2015
'HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact'
JOURNAL OF VIRAL HEPATITIS
22,
(4)
399-408
, DOI
PEARL
2014
'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis'
Lancet
384,
(9958)
1953-1997
2014
'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis'
Lancet
384,
(9958)
1953-1997
, DOI
2014
'Impaired functional capacity in potential liver transplant candidates predicts short-term mortality before transplantation'
Liver Transpl
20,
(9)
1081-1088
, DOI
2014
'Role of Mycophenolate Mofetil for the Treatment of Autoimmune Hepatitis—An Observational Study'
Journal of Clinical and Experimental Hepatology
4,
(3)
221-225
, DOI
2014
'Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality'
BMC Gastroenterol
14,
, DOI
PEARL
2014
'Historical epidemiology of hepatitis C virus (HCV) in selected countries'
J Viral Hepat
21 Suppl 1,
5-33
, DOI
2014
'Strategies to manage hepatitis C virus (HCV) disease burden'
J Viral Hepat
21 Suppl 1,
60-89
, DOI
2014
'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm'
J Viral Hepat
21 Suppl 1,
34-59
, DOI
2014
'Polymorphic differences in SOD-2 may influence HCV viral clearance'
J Med Virol
86,
(6)
941-947
, DOI
2014
'CD81 sequence and susceptibility to hepatitis C infection'
JOURNAL OF MEDICAL VIROLOGY
86,
(1)
162-168
, DOI
2013
'Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection'
Hepatology
58,
(3)
881-889
, DOI
2013
'Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts'
Ann Intern Med
158,
(4)
235-245
, DOI
2012
'Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection'
J Viral Hepat
19,
(7)
501-508
, DOI
2012
'POTENTIAL IMPACT OF PROTEASE INHIBITORS IN THE SOUTH WEST PENINSULA HEPATITIS C POPULATION'
GUT
61,
A140-A141
, DOI
2012
'Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon alpha-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis'
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
24,
(5)
543-550
, DOI
2011
'OP04 Synergistic influence of tapasin and HLA class I protection against chronic Hepatitis C virus infection'
Gut
60,
(Suppl 2)
A51-A52
, DOI
2011
'P45 Natural killer cell cytotoxicity is enhanced in injection drug users with apparent resistance to hepatitis C virus infection'
Gut
60,
(Suppl 2)
A21-A22
, DOI
2011
'P80 Patient characteristics and outcomes in a 'Hub and Spoke Model' for liver transplantation provision: The South West Liver Unit/King's College Experience'
Gut
60,
(Suppl 2)
A37-A37
, DOI
2011
'A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection'
GASTROENTEROLOGY
141,
(1)
320-U419
, DOI
2011
'Treatment of autoimmune hepatitis: a review of current and evolving therapies'
J Gastroenterol Hepatol
26,
(4)
619-627
, DOI
2011
'Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation'
J Infect Dis
203,
(6)
847-853
, DOI
2010
'Consistent Beneficial Effects of Killer Cell Immunoglobulin-Like Receptor 2DL3 and Group 1 Human Leukocyte Antigen-C Following Exposure to Hepatitis C Virus'
HEPATOLOGY
51,
(4)
1168-1175
, DOI
2010
'Limitations of the Algorithm for the SAFE Biopsy: A Noninvasive Fibrosis Measure in Chronic Hepatitis C'
HEPATOLOGY
51,
(1)
354-355
, DOI
2009
'Elastography for the non-invasive assessment of liver disease: limitations and future developments'
GUT
58,
(8)
1171-1172
2009
'ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY'
JOURNAL OF HEPATOLOGY
50,
S385-S385
, DOI
2008
'Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection'
Clin Exp Immunol
152,
(3)
538-541
, DOI
2008
'Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility analysis'
British Journal of Cancer
98,
(7)
1166-1175
, DOI
PEARL
2007
'Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis'
Health Technol Assess
11,
(34)
1-206
2007
'Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis'
Health Technology Assessment
11,
(34)
1-+
2006
'Case finding for hepatitis C in primary care: a cost utility analysis'
Fam Pract
23,
(4)
393-406
, DOI
2006
'Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression'
Int J STD AIDS
17,
(1)
67-69
, DOI
2006
'The cost-effectiveness of testing for hepatitis C in former injecting drug users'
Health Technology Assessment
10,
(32)
1-+
2005
'Polymorphisms in the IL-12B gene and outcome of HCV infection'
J Interferon Cytokine Res
25,
(5)
271-276
, DOI
2005
'Non-travel-associated Hepatitis C in England and Wales: Demographic, clinical, and molecular epidemiological characteristics'
Journal of Infectious Diseases
192,
(7)
1166-1172
2004
'HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection'
Science
305,
(5685)
872-874
, DOI
2004
'Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity'
J Med Virol
72,
(3)
370-376
, DOI
2004
'Screening for hepatitis C virus in the Dartmoor prison population: an observational study'
Journal of Public Health
26,
(4)
372-375
2003
'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT'
AMERICAN JOURNAL OF GASTROENTEROLOGY
98,
(7)
1588-1593
, DOI
2003
'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT'
Am J Gastroenterol
98,
(7)
1588-1593
, DOI
2003
'Traditional Chinese medicine in the treatment of chronic HCV infection'
Gut
52,
(5)
2002
'Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy'
Liver
22,
(5)
404-412
2002
'Investigation and treatment of ascites'
Clin Med (Lond)
2,
(4)
310-313
2002
'Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases'
J Hepatol
36,
(2)
295-301
2002
'Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center'
Hepatogastroenterology
49,
(44)
524-528
2001
'Liver transplantation in adults coinfected with HIV'
Transplantation
72,
(10)
1684-1688
2001
'Liver Transplantation in Adults Coinfected With HIV. Transplantation 2001; 72: 1684'
Transplantation
72,
(10)
1594-1595
, DOI
2000
'Liver histology and progression of fibrosis in individuals with chronic hepatitis C virus infection and persistently normal ALT'
HEPATOLOGY
32,
(4)
285A-285A
2000
'Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)'
J Am Acad Dermatol
43,
(2 Pt 2)
403-408
2000
'Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg)'
Journal of the American Academy of Dermatology
43,
(2)
403-408
, DOI
2000
'Hepatitis C virus–specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C'
Gastroenterology
118,
(2)
346-355
, DOI
1999
'HBV + HCV = HCC?'
Gut
45,
(2)
168-169
1999
'The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre'
Gut
44,
(4)
563-567
, DOI
1999
'Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia'
Gut
44,
(3)
424-429
1998
'Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia'
J Hepatol
29,
(2)
207-213
1997
'Hepatitis in alcohol and drug misusers: practical issues'
Addiction Biology
2,
(4)
411-420
, DOI
1996
'Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults'
J R Soc Med
89,
(7)
401-402
1996
'Bile acid malabsorption in HIV infected patients with chronic diarrhoea'
Aust N Z J Med
26,
(3)
368-371
1994
'Cutaneous manifestations of mycobacterial infection in patients with AIDS'
Br J Dermatol
130,
(1)
111-114
1992
'Case report: pneumatosis intestinalis occurring in association with cryptosporidiosis and HIV infection'
Clin Radiol
46,
(6)
410-411
1992
'Rapid high-flux dialysis can cure uraemic peripheral neuropathy'
Nephrol Dial Transplant
7,
(6)
539-540
Letters
2002
'Re: Whither smooth muscle antibodies in the third millennium?'
J Clin Pathol
55,
(7)
558-559
1993
'Re-emergence of tuberculosis'
BMJ
306,
(6882)
Chapters
2013
'Clinical and pathological features, and diagnosis'
Viral Hepatitis: Fourth Edition
442-449
, DOI
2011
'Systemic Therapy for Hepatocellular Carcinoma: Future Directions'
Clinical Dilemmas in Primary Liver Cancer
199-211
, DOI
Conference Papers
2018
'Selonsertib in Combination with Prednisolone for the Treatment of Severe Alcoholic Hepatitis: A Phase 2 Randomized Controlled Trial'
8A-9A
2017
'A NOVEL FUNCTIONAL BIOASSAY PREDICTS 90-DAY SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS'
A99-A100
, DOI
PEARL
2017
'Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study'
S1061-S1061
, DOI
2017
'Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study'
S503-S504
, DOI
2017
'Successful treatment of patients with HCV GT3 infection and cirrhosis with elbasvir/grazoprevir plus sofosbuvir does not correct insulin resistance by 12 weeks post-treatment'
S504-S505
, DOI
2016
'C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks'
39A-40A
2016
'Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin'
455A-456A
2016
'Sustained viral clearance of HCV with DAA treatment is associated with restoration of effector T cell phenotype'
745A-745A
2016
'SOFOSBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS IN HCV INFECTED PATIENTS PREVIOUSLY TREATED WITH PLACEBO: RESULTS OF THE DEFERRED TREATMENT STUDY (GS-US-342-1446 STUDY)'
S827-S828
2015
'PTH-100 A comparative gene expression study between individuals with apparent resistance, spontaneous clearance, or chronic infection from hcv'
A452.1-A452
, DOI
2015
'PTH-124 Liver transplant outcomes in patients with care devolved to a non-transplanting centre: south west liver unit experience'
A462.2-A463
, DOI
2015
'LP11 : Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year'
S268-S269
, DOI
2014
'P210 ALTERATIONS IN CXCR3/CXCL10 BUT NOT CCR5 IN HCV ARE ASSOCIATED WITH VIRAL INHIBITION WITH INTERFERON-FREE DIRECT ACTING ANTIVIRAL THERAPY'
S136-S136
, DOI
2014
'P790 REDUCING THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ENGLAND'
S333-S334
, DOI
2014
'High-Level Resistance to Hepatitis C - A Possible Role for Innate Immunity'
1064A-1064A
2014
'Neutralising anti-envelope antibodies in uninfected individuals that are repeatedly exposed to HCV'
1057A-1057A
2013
'ARE CURRENT TREATMENT RATES SUFFICIENT TO REDUCE HCV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS? MODEL PROJECTIONS IN SEVEN UK SETTINGS'
S356-S356
, DOI
2013
'THE USE OF CARDIOPULMONARY EXERCISE TESTING IN PREDICTING PRE- AND POST-OPERATIVE MORTALITY IN LIVER TRANSPLANT CANDIDATES'
S412-S412
, DOI
2011
'Synergistic influence of tapasin and HLA class I protection against chronic hepatitis C virus infection'
173-173
2011
'NATURAL KILLER CELL CYTOTOXICITY IS ENHANCED IN INJECTION DRUG USERS WITH APPARENT RESISTANCE TO HEPATITIS C VIRUS INFECTION'
1322A-1322A
2011
'ABSENCE OF IL-28B PROTECTION IN INDIVIDUALS EXPOSED TO HEPATITIS C VIRUS DEMONSTRATES DISCRETE GENETIC PATHWAYS FOR PROTECTION AGAINST CHRONIC HCV INFECTION'
S38-S39
, DOI
2010
'INDIVIDUALIZED CONCENTRATION MONITORED HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON TO HEPATITIS C GENOTYPE 1 PATIENTS WITH PREVIOUS NONRESPONSE'
710A-711A
2010
'PACIFIC: A PHASE III, RANDOMIZED, MULTICENTER, DOSE ESCALATION, EFFICACY AND SAFETY STUDY EXAMINING THE EFFECTS OF TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CHILD'S A OR B CIRRHOSIS IN CHRONIC HEPATITIS C VIRUS INFECTION'
710A-710A
2010
'PTU-069 Predictors of hepatitis C treatment outcome in genotype 1 patients in a “real world” setting'
A77.1-A77
, DOI
2009
'ASSOCIATION OF HLA AND NK CELL INHIBITORY RECEPTOR WITH APPARENT RESISTANCE TO HEPATITIS C INFECTION'
386A-386A
2009
'CELLULAR DISTRIBUTION OF CLAUDIN 1 IN LIVER TISSUE IN HEPATITIS C AND OTHER LIVER DISEASES'
950A-950A
2009
'CYTOKINE PROFILES IN HCV EXPOSED BUT UNINFECTED CASES WITH APPARENT RESISTANCE TO HCV INFECTION'
936A-936A
2009
'LONGITUDINAL ANALYSIS OF HEPATITIS C VIRUS SPECIFIC T CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS'
A17-A17
2009
'LONGITUDINAL ANALYSIS OF HCV SPECIFIC T-CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS'
S326-S326
, DOI
2008
'Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection'
United States
1749-1755
, DOI
2008
'Audit of management of alcohol withdrawal at derriford hospital'
A72-A72
2008
'Mycophenolate mofetil in patients with refractory autoimmune hepatitis'
A71-A72
2007
'HCV-specific cellular immune responses in intravenous drug users without HCV infection'
240A-241A
2007
'Interleukin 12B gene polymorphism and apparent resistance to HCV infection'
890A-891A
2007
'Single nucleotide polymorphism of the SRB1 gene and susceptibility to HCV infection'
A134-A135
2006
'Late spontaneous clearance of hepatitis C'
A43-A43
2005
'HCV-specific cellular immune responses in subjects exposed to but uninfected by HCV'
A6-A7
2005
'HCV-specific cellular immune responses in subjects exposed, but uninfected by HCV'
A712-A712
PEARL
2004
'Endoscopic sphincterotomy is sufficient treatment for most post cholecystectomy bile leaks'
A44-A44
2003
'IL-12 gene polymorphism and outcome of HCV infection'
356A-356A
2003
'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA'
2002
'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA'
552A-552A
2002
'Traditional Chinese medicine in the treatment of chronic HCV infection'
569A-569A
2000
'Reactivation of latent hepatitis B virus infection with HIV related immunosuppression'
454A-454A
1999
'The association of the Arg25Pro polymorphism in the TGF beta 1 gene with fibrosis in chronic hepatitis C patients'
331A-331A
1999
'HCV-specific immune responses in HCV exposed but uninfected cases'
A97-A97
1998
'HCV-specific T helper cell responses in HCV exposed but uninfected cases'
200A-200A
1998
'HLA class III and class II alleles in hepatitis C virus infection and outcome'
159-160
1998
'Interferon induced virus specific T helper cell responses are associated with viral clearance in chronic HCV infection'
155-155
1998
'Mutations within a promiscuous immunodominant epitope in hepatitis B core protein and their effect on T helper cell response'
156-157
1998
'The influence of the HLA class II allele DQB1*0301 on HCV specific T helper cell responses'
A21-A21
1997
'Interferon induced virus specific T helper cell responses are associated with viral clearance in chronic HCV infection'
1111-1111
1997
'Reduced production of interleukin-12 by PBMC from patients with chronic hepatitis C'
1121-1121
1997
'T helper cell response to mutations within a promiscuous immunodominant epitope in acute and chronic hepatitis B'
1953-1953
1997
'Tumor necrosis factor gene polymorphisms in hepatitis C virus infection'
1413-1413
1997
'Beneficial in vitro effects of tucaresol on the immune response to hepatitis C virus'
TH119-TH119
1996
'A multispecific T lymphocyte response to hepatitis C virus proteins occurs in patients with viral clearance and persists many years after exposure'
503-503
1996
'Evidence that HLA class II genotype may be associated with clearance of hepatitis C virus'
99-99
Reports
2006
The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Posters
0
'Intermediate (CD14++CD16+) monocytes from patients with acute severe alcoholic hepatitis are activated and functionally similar to classical (CD14++CD16−) monocytes'
0
0
, DOI